Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zonisamide in Early Parkinson Disease
NCT01766128Phase 3Withdrawn
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Feb 2013
- Primary completion
- Feb 2013
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Zonisamide Arm with Placebo Arm (2 arms). Primary endpoint: Time to need for dopaminergic therapy at 6 months. Planned start Feb 2013; status: withdrawn.
02
Drugs
zonisamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01766128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01766128.